MSH2 and prostate carcinoma: This is probably why, in previous retrospective studies the high incidence of urothelial cancers in path_MSH2 carriers was not clearly described, the lower incidence of CRC in female than male path_MSH2 carriers probably was an artifact due to competing causes of death, and the later onset prostate cancers were also missed because of competing causes of death.